Samsung Bioepis Celebrates Soliris Success

Phase I Results For SB12 Eculizumab Biosimilar Candidate Demonstrate Equivalence

 
• By Dave Wallace

Samsung Bioepis has revealed positive Phase I trial results for its SB12 proposed eculizumab biosimilar rival to Soliris.

clinical trials
Samsung Bioepis has announced Phase I trial results for its eculizumab • Source: Shutterstock

More from Biosimilars

More from Products